DOCSLIB.ORG

Paediatric Nephrology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paediatric Nephrology Oxford Specialist Handbooks in Paediatrics Paediatric Nephrology Second edition Lesley Rees MD, FRCPCH Consultant Paediatric Nephrologist Gt Ormond St Hospital for Children NHS Trust London, UK Paul A. Brogan MSc, PhD, MRCP, FRCPCH Senior Lecturer and Honorary Consultant Paediatric Rheumatologist Gt Ormond St Hospital for Children NHS Trust London, UK Detlef Bockenhauer PhD, FRCPCH Consultant Paediatric Nephrologist Gt Ormond St Hospital for Children NHS Trust London, UK Nicholas J.A. Webb DM, FRCP, FRCPCH Consultant Paediatric Nephrologist Royal Manchester Children’s Hospital Manchester, UK 1 1 Great Clarendon Street, Oxford OX2 6DP United Kingdom Oxford University Press is a department of the University of Oxford. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries © Oxford University Press 2012 The moral rights of the authors have been asserted First edition published 2007 Second edition published 2012 Impression: 1 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above You must not circulate this work in any other form and you must impose this same condition on any acquirer British Library Cataloguing in Publication Data Data available Library of Congress Cataloging-in-Publication Data Paediatric nephrology / Lesley Rees . [et al.].—2nd ed. p. ; cm.—(Oxford specialist handbooks in paediatrics) Rev. ed. of: Paediatric nephrology / Lesley Rees, Nicolas J.A. Webb, Paul A. Brogan. 2007. Includes bibliographical references and index. ISBN 978–0–19–960137–0 (alk. paper) I. Rees, Lesley, 1951-II. Rees, Lesley, 1951-Paediatric nephrology. III. Series: Oxford specialist handbooks in paediatrics. [DNLM: 1. Kidney Diseases—Handbooks. 2. Child. 3. Infant. WS 39] LC classifi cation not assigned 618.92’61–dc23 2011033028 ISBN 978–0–19–960137–0 Printed in China on acid-free paper by Asia Pacifi c Offset Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breast-feeding Links to third party websites are provided by Oxford in good faith and for information only. Oxford disclaims any responsibility for the materials contained in any third party website referenced in this work. iii Preface to second edition Following on from the success of the fi rst edition of our handbook, we have produced a second edition which has been totally updated. In par- ticular, we have brought in our colleague, Dr Bockenhauer. We have used his expertise to ensure that this second edition is fully up-to-date in genetics. In addition, he has developed and simplifi ed the concepts of electrolyte balance by going back to basic renal physiology. Our original aim in producing a handbook that is a comprehensive and clinically-orientated guide to the management of children with all forms of renal disease remains. We have continued to try to make the text as practical as possible in the expectation that this will become the fi rst text that the paediatrician refers to when presented with a child with an acute or chronic kidney disorder. The book provides up-to-date information for the general paediatrician and the paediatric nephrologist. It is pocket sized so that it is easily referred to in the clinical setting and uses a system of bullet points to facilitate this. It covers both common conditions seen by all paediatricians during the day-to-day care of patients on a general paediatric ward or in the outpatient clinic, and also those seen rarely and usually in specialized paediatric nephrology centres in collaboration with local units. The focus is heavily on investigation and management and there is intentionally little emphasis on basic pathogenesis and disease mechanisms. Where possible we have made evidence-based recommendations, though in the many instances where high quality evidence is lacking, we make recommendations based on the authors’ personal experience and current best practice. All of the chapters have been written by the four authors, who are experienced consultants at two large UK Children’s Hospitals, although we have received signifi cant input from a number of our colleagues (listed on pages vi and vii) to whom we are most grateful. We would also like to thank Helen Liepman at Oxford University Press for seeing the handbook through from conception to delivery. LR, PB, DB, and NW 2011 This page intentionally left blank v Contents Contributors vi Symbols and abbreviations viii 1 Patient assessment 1 2 The neonate 43 3 Congenital abnormalities 49 4 Urinary tract infection 75 5 Enuresis 91 6 Homeostasis 99 7 Tubular disease 139 8 Renal calculi and nephrocalcinosis 173 9 Glomerular disease 181 10 Systemic disease affecting the kidney 225 11 Vasculitis 275 12 Infections and the kidney 315 13 Renal cystic diseases and ciliopathies 319 14 Syndromes associated with renal diseases 335 15 Renal tumours 347 16 Hypertension 353 17 Acute kidney injury 377 18 Chronic kidney disease 409 19 Chronic peritoneal dialysis 465 20 Extracorporeal treatment 483 21 Transplantation 511 22 Drug prescribing 573 23 Psychosocial issues 581 Appendix: Supplementary information 599 Index 625 vi Contributors Staff at Gt Ormond St Hospital for Children NHS Trust: Dr William van’t Hoff Ms Liz Wright Consultant Paediatric Clinical Nurse Specialist in Nephrologist Extracorporeal Treatments Dr Kjell Tullus Mr David Fisher Consultant Paediatric Nurse Counsellor Nephrologist Dr Vic Larcher Dr Steven Marks Consultant Paediatrician Consultant Paediatric Nephrologist Professor Robert Kleta Professor of Paediatric Professor Neil Sebire Nephrology Consultant Paediatric Pathologist Professor Michael Dillon Ms Vanessa Shaw Emeritus Professor of Paediatric Chief Paediatric Renal Dietician Nephrology Ms Sue Patey Dr Despina Eleftheriou Senior Paediatric Renal Pharmacist Honorary Consultant Paediatric Rheumatologist Ms Eileen Brennan Nurse Consultant in Paediatric Dr Despoina Maritsi Nephrology Clinical Fellow in Paediatric Rheumatology Ms Michelle Cantwell Clinical Nurse Specialist in Peritoneal Dialysis Staff at Royal Manchester Children’s Hospital: Dr Mohan Shenoy Dr Malcolm Lewis Consultant Paediatric Nephrologist Consultant Paediatric Nephrologist Ms Hong Thoong Lead Pharmacist—Paediatric Dr Nick Plant Medicine Consultant Paediatric Nephrologist Dr Bernadette Brennan Consultant Paediatric Oncologist Dr Neville Wright Consultant Paediatric Radiologist Mr Alan Dickson Consultant Paediatric Urologist CONTRIBUTORS vii Elsewhere: Dr Declan de Freitas Dr Jonathan Evans Consultant Nephrologist Consultant Paediatric Nephrologist Manchester Royal Infi rmary, Queens Medical Centre, Manchester, UK Nottingham, UK Dr Judith E Worthington Dr Ian Roberts Principal Clinical Scientist Consultant Renal Histopathologist Manchester Royal Infi rmary, John Radcliffe Infi rmary, Manchester, UK Oxford, UK Dr Bronwyn Kerr Dr Annett Birgitta Kranz Consultant Clinical Geneticist, Consultant Paediatric St Mary’s Hospital, Nephrologist Manchester, UK Universitätsklinikum Münster Klinik u.Poliklinik Dr Kay Metcalfe f.Kinderheilkunde, Germany Consultant Clinical Geneticist, St Mary’s Hospital, Manchester, UK viii Symbols and abbreviations G -GT gamma-glutamyltransferase AA amyloid-A AAV ANCA-associated vasculitis Ab antibody ABMR antibody-mediated rejection ABPM ambulatory blood pressure monitoring ACEI angiotensin converting enzyme inhibitor aCGH array comparative genomic hybridization (assay for chromosomal microdeletions/insertions) ACL anticardiolipin antibody ACR American College of Rheumatology AD autosomal dominant ADH anti-diuretic hormone ADPKD autosomal dominant polycystic kidney disease AFP alpha fetoprotein AG anion gap AKI acute kidney injury AL amyloid-L ALG anti-lymphocyte globulin ALMS Asprevas Lupus Management Study ALP alkaline phosphatase ALT alanine transaminase ANA antinuclear antibodies ANCA anti-neutrophil cytoplasmic antibody anti-ds-DNA anti double stranded DNA AP alternative pathway APA antiphospholipid antibodies APC antigen-presenting cells APD automated peritoneal dialysis APS antiphospholipid syndrome APTT activated prothrombin time AQ2 aquaporin 2 AR autosomal recessive ARB angiotensin II receptor blocker ARPKD autosomal recessive polycystic kidney disease AS Alport syndrome ASOT anti-streptolysin O titre SYMBOLS AND ABBREVIATIONS ix AST aspartate aminotransferase ATG anti-thymocyte globulin ATN acute tubular necrosis AV arteriovenous AVP arginine vasopressin AXR abdominal X-ray BCG Bacille Calmette-Guérin bd twice daily BHS British Hypertension
Load more

Recommended publications
  • MYH9-Related Platelet Disorders
    Reprinted with permission from Thieme Medical Publishers (Semin Thromb Hemost 2009;35:189-203) Homepage at www.thieme.com MYH9-Related Platelet Disorders Karina Althaus, M.D.,1 and Andreas Greinacher, M.D.1 ABSTRACT Myosin heavy chain 9 (MYH9)-related platelet disorders belong to the group of inherited thrombocytopenias. The MYH9 gene encodes the nonmuscle myosin heavy chain IIA (NMMHC-IIA), a cytoskeletal contractile protein. Several mutations in the MYH9 gene lead to premature release of platelets from the bone marrow, macro- thrombocytopenia, and cytoplasmic inclusion bodies within leukocytes. Four overlapping syndromes, known as May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, and Sebastian platelet syndrome, describe different clinical manifestations of MYH9 gene mutations. Macrothrombocytopenia is present in all affected individuals, whereas only some develop additional clinical manifestations such as renal failure, hearing loss, and presenile cataracts. The bleeding tendency is usually moderate, with menorrhagia and easy bruising being most frequent. The biggest risk for the individual is inappropriate treatment due to misdiagnosis of chronic autoimmune thrombocytopenia. To date, 31 mutations of the MYH9 gene leading to macrothrombocytopenia have been identified, of which the upstream mutations up to amino acid 1400 are more likely associated with syndromic manifestations than the downstream mutations. This review provides a short history of MYH9-related disorders, summarizes the clinical and laboratory character- istics, describes a diagnostic algorithm, presents recent results of animal models, and discusses aspects of therapeutic management. KEYWORDS: MYH9 gene, nonmuscle myosin IIA, May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Sebastian platelet syndrome, macrothrombocytopenia The correct diagnosis of hereditary chronic as isolated platelet count reductions or as part of thrombocytopenias is important for planning appropri- more complex clinical syndromes.
    [Show full text]
  • Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series
    DOCTOR OF MEDICAL SCIENCE Patients with AS constitute 2.3% (11/476) of the renal transplant population at the Mayo Clinic [24], and 1.3% of 1,000 consecutive kidney transplant patients from Sweden [25]. Approximately 0.56% Alport syndrome of the European dialysis population suffers from AS [26], and simi- lar figures have been found in other series. AS accounts for 18% of Molecular genetic aspects the patients undergoing dialysis or having received a kidney graft in 2003 in French Polynesia [27]. A common founder mutation was in Jens Michael Hertz this area. In Denmark, the percentage of patients with AS among all patients starting treatment for ESRD ranges from 0 to 1.21% (mean: 0.42%) in a twelve year period from 1990 to 2001 (Danish National This review has been accepted as a thesis together with nine previously pub- Registry. Report on Dialysis and Transplantation in Denmark 2001). lished papers by the University of Aarhus, February 5, 2009, and defended on This is probably an underestimate due to the difficulties of establish- May 15, 2009. ing the diagnosis. Department of Clinical Genetics, Aarhus University Hospital, and Faculty of Health Sciences, Aarhus University, Denmark. 1.3 CLINICAL FEATURES OF X-LINKED AS Correspondence: Klinisk Genetisk Afdeling, Århus Sygehus, Århus Univer- 1.3.1 Renal features sitetshospital, Nørrebrogade 44, 8000 Århus C, Denmark. AS in its classic form is a hereditary nephropathy associated with E-mail: [email protected] sensorineural hearing loss and ocular manifestations. The charac- Official opponents: Lisbeth Tranebjærg, Allan Meldgaard Lund, and Torben teristic renal features in AS are persistent microscopic hematuria ap- F.
    [Show full text]
  • Case Report Two Cases of the MYH9 Disorder Fechtner Syndrome Diagnosed from Observation of Peripheral Blood Cells Before End-Stage Renal Failure
    Hindawi Case Reports in Nephrology Volume 2019, Article ID 5149762, 6 pages https://doi.org/10.1155/2019/5149762 Case Report Two Cases of the MYH9 Disorder Fechtner Syndrome Diagnosed from Observation of Peripheral Blood Cells before End-Stage Renal Failure Shin Teshirogi,1 Jun Muratsu ,1 Hidenori Kasahara,1 Ken Terashima,1 Sho Miki,1 Tomohiro Minami,1 Yujiro Okute,1 Suguru Yoneda,1 Atsuyuki Morishima ,1 Shinji Kunishima,2 and Katsuhiko Sakaguchi 1 1Department of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Nakanoshima, Kita-ku, Osaka 530-0005, Japan 2Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan Correspondence should be addressed to Jun Muratsu; [email protected] Received 22 June 2019; Revised 21 August 2019; Accepted 4 October 2019; Published 26 November 2019 Academic Editor: Yoshihide Fujigaki Copyright © 2019 Shin Teshirogi et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. As a MYH9 disorder, Fechtner syndrome is characterized by nephritis, giant platelets, granulocyte inclusion bodies (Döhle-like bodies), cataract, and sensorineural deafness. Observation of peripheral blood smear for the presence of thrombocytopenia, giant platelets, and granulocyte inclusion bodies (Döhle-like bodies) is highly important for the early diagnosis of MYH9 disorders. In our two cases, sequencing analysis of the MYH9 gene indicated mutations in exon 24. Both cases were diagnosed as the MYH9 disorders Fechtner syndrome before end-stage renal failure on the basis of the observation of peripheral blood smear.
    [Show full text]
  • MYH9 Mutation, the Hidden Face of Diverse Disease
    Urology & Nephrology Open Access Journal Case Report Open Access MYH9 mutation the hidden face of diverse disease spectrum - from renal perspective; renal perspective of MYH9 mutation Abstract Volume 5 Issue 4 - 2017 MYH9 (myosin heavy chain 9)-mutation is a frequent genetic disorder among African- 1 1 Americans and rare in Caucasians that can lead to dramatic deterioration of renal function Assel Rakhmetova, Pakesh Baishya, Pouneh 1 2 1 and as a consequence, end stage renal disease (ESRD). The clinical presentation of MYH9 Dokouhaki, Abdullah Alabbas, Kim Solez 1 mutations includes five syndromes: May-Hegglin anomaly, Sebastian, Fechtner, Epstein Department of laboratory medicine and pathology, University syndromes and isolated sensorineural deafness. The diagnosis is challenging to establish of Alberta hospital, Canada 2Department of pediatrics, division of nephrology, University of due to non-specific presentation that requires exclusion of a vast number of other entities. Alberta hospital, Canada Renal biopsy is not commonly performed but it may reveal non-specific findings such as mesangial expansion with hypercellularity, focal segmental glomerulosclerosis (FSGS) Correspondence: Pakesh Baishya, Department of laboratory and/or global glomerulosclerosis usually with no immune complex deposition. The medicine and pathology, University of Alberta hospital, immunostaining study for alpha-smooth muscle actin (SMA) can be valuable to perform Edmonton, Alberta, Canada, Tel 1 5875328105, in patients suspected to have MYH9 mutations in order to detect early FSGS. Additional Email studies for patients presenting with thrombocytopenia, decreasing glomerular filtration rate, proteinuria and haematuria are suggested. Here, we report a child with classic clinical picture Received: December 10, 2017 | Published: October 26, 2017 of MYH9 genetic disorder that presented with early focal segmental glomerulosclerosis with possible concurrent C1q nephropathy.
    [Show full text]
  • Article Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial
    Article Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis Angela K. Muriithi,* Samih H. Nasr,† and Nelson Leung* Summary Background and objectives Urine eosinophils (UEs) have been shown to correlate with acute interstitial nephritis (AIN) but the four largest series that investigated the test characteristics did not use kidney biopsy as the gold standard. *Division of Nephrology and Hypertension, Design, setting, participants, & measurements This is a retrospective study of adult patients with biopsy-proven Department of diagnoses and UE tests performed from 1994 to 2011. UEs were tested using Hansel’s stain. Both 1% and 5% UE Internal Medicine, cutoffs were compared. Mayo Clinic, Rochester, Minnesota; and †Department of Results This study identified 566 patients with both a UE test and a native kidney biopsy performed within a week Laboratory Medicine of each other. Of these patients, 322 were men and the mean age was 59 years. There were 467 patients with and Pathology. Mayo pyuria, defined as at least one white cell per high-power field. There were 91 patients with AIN (80% was drug Clinic, Rochester, induced). A variety of kidney diseases had UEs. Using a 1% UE cutoff, the comparison of all patients with AIN to Minnesota those with all other diagnoses showed 30.8% sensitivity and 68.2% specificity, giving positive and negative ’ Correspondence: likelihood ratios of 0.97 and 1.01, respectively. Given this study s 16% prevalence of AIN, the positive and Dr. Angela K. Muriithi, negative predictive values were 15.6% and 83.7%, respectively. At the 5% UE cutoff, sensitivity declined, but Mayo Clinic, Division specificity improved.
    [Show full text]
  • A Complicated Case of Von Hippel-Lindau Disease
    Postgrad Med J 2001;77:471–480 471 Postgrad Med J: first published as 10.1136/pmj.77.909.478 on 1 July 2001. Downloaded from SELF ASSESSMENT QUESTIONS A complicated case of von Hippel-Lindau disease G Thomas, R Hillson Answers on p 481. A 17 year old female shop assistant presented with a three week history of generalised headache, associated with nausea, vomiting, and vertigo. She had no past medical history, and was taking no regular medication. Her mother was currently receiving radiotherapy for anaplastic carcinoma of the thyroid gland. On examination she had an ataxic gait, bilateral papilloedema, and horizontal nystagmus to right lateral gaze. Left sided dysdiadokinesis and hyper-reflexia were demonstrated. Power and sensation were preserved. Computed tom- ography of the brain revealed a cystic lesion within the left cerebellum. Subsequent mag- netic resonance imaging (MRI) revealed a sec- ond, non-cystic lesion within the region of the right vermis (fig 1). Both images were consist- ent with cerebellar haemangioblastomata. A posterior fossa craniotomy was performed, with successful excision of both tumours. She made an uneventful recovery, with complete resolution of all symptoms, and was subse- Figure 3 MIBG isotope quently discharged. uptake scan. During a follow up outpatient appointment Figure 1 MRI of the brain. six months later, she complained of frequent panic attacks, associated with sweating and http://pmj.bmj.com/ palpitation that had begun two months earlier. These episodes were precipitated by exercise or excitement. She gave no history of heat intoler- Department of ance, weight loss, or diarrhoea. Examination Diabetes and was entirely normal.
    [Show full text]
  • Genetic Disorders of the Glomerular Filtration Barrier
    CJASN ePress. Published on April 23, 2020 as doi: 10.2215/CJN.11440919 Genetic Disorders of the Glomerular Filtration Barrier Anna S. Li,1,2 Jack F. Ingham,1 and Rachel Lennon 1,3 Abstract The glomerular filtration barrier is a highly specialized capillary wall comprising fenestrated endothelial cells, podocytes, and an intervening basement membrane. In glomerular disease, this barrier loses functional integrity, allowing the passage of macromolecules and cells, and there are associated changes in both cell morphology and the extracellular matrix. Over the past three decades there has been a transformation in our understanding about glomerular disease, fueled by genetic discovery, and this is leading to exciting advances in our knowledge about 1Division of Cell- glomerular biology and pathophysiology. In current clinical practice, a genetic diagnosis already has important Matrix Biology and implications for management ranging from estimating the risk of disease recurrence post-transplant to the life- Regenerative changing advances in the treatment of atypical hemolytic uremic syndrome. Improving our understanding about Medicine, Wellcome Centre for Cell-Matrix the mechanistic basis of glomerular disease is required for more effective and personalized therapy options. In this Research, School of review we describe genotype and phenotype correlations for genetic disorders of the glomerular filtration barrier, Biological Sciences, with a particular emphasis on how these gene defects cluster by both their ontology and patterns of glomerular Faculty of Biology, pathology. Medicine and Health, CJASN ccc–ccc Manchester Academic 15: , 2020. doi: https://doi.org/10.2215/CJN.11440919 Health Science Centre, The University of Manchester, Introduction fenestrae that are 70–100 nm in diameter and covered Manchester, United .
    [Show full text]
  • The First Case of MYH9 Related Disorder in Serbia Kongenitalna Trombocitopenija Sa Nefritisom – Prvi Bolesnik Sa MYH9 Poremeüajem U Srbiji
    Vojnosanit Pregl 2014; 71(4): 395–398. VOJNOSANITETSKI PREGLED Strana 395 UDC: 575:61]:[616.155.2-056.7:616.61 CASE REPORTS DOI: 10.2298/VSP121127001K Congenital thrombocytopenia with nephritis – The first case of MYH9 related disorder in Serbia Kongenitalna trombocitopenija sa nefritisom – prvi bolesnik sa MYH9 poremeüajem u Srbiji Miloš Kuzmanoviü*†, Shinji Kunishima‡, Jovana Putnik†, Nataša Stajiü*†, Aleksandra Paripoviü†, Radovan Bogdanoviü*† *Faculty of Medicine, University of Belgrade, Belgrade, Serbia; †Institute of Mother and Child Health Care of Serbia „Dr Vukan ýupiü“, Belgrade, Serbia; ‡Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan Abstract Apstrakt Introduction. The group of autosomal dominant disor- Uvod. Grupu autozomno dominantnih poremeýaja – Ep- ders – Epstein syndrome, Sebastian syndrome, Fechthner steinov sindrom, Sebastianov sindrom, Fechthnerov sindrom syndrome and May-Hegglin anomaly – are characterised i May-Hegglinovu anomaliju – odlikuju trombocitopenija sa by thrombocytopenia with giant platelets, inclusion bod- džinovskim trombocitima, inkluzije u granulocitima, kao i ra- ies in granulocytes and variable levels of deafness, dis- zliÿita zastupljenost gluvoýe, poremeýaja vida i funkcije bub- turbances of vision and renal function impairment. A rega. Genetska osnova ovih sindroma su mutacije u genu za common genetic background of these disorders are mu- teški lanac nemišiýnog miozina IIA, a za ovu grupu sindroma tations in MYH9 gene, coding for the nonmuscle myosin predložen je naziv bolesti vezane za MYH9. Diferencijalna heavy chain IIA. Differential diagnosis is important for dijagnoza prema trombocitopenijama druge etiologije je zna- the adequate treatment strategy. The aim of this case re- ÿajna zbog pravilnog izbora terapijskih postupaka. Cilj rada port was to present a patient with MYH9 disorder in bio je prikaz bolesnika sa MYH9 poremeýajem u Srbiji.
    [Show full text]
  • Medical Attention for Nephropathy)
    PT‐ 2020 Measure Value Set_CDC (Medical Attention for Nephropathy) Numerator Value Set Name Code Definition Code System Urine Protein Tests 81000 CPT Urine Protein Tests 81001 CPT Urine Protein Tests 81002 CPT Urine Protein Tests 81003 CPT Urine Protein Tests 81005 CPT Urine Protein Tests 82042 CPT Urine Protein Tests 82043 CPT Urine Protein Tests 82044 CPT Urine Protein Tests 84156 CPT Urine Protein Tests 3060F Positive microalbuminuria test result documented and reviewed (DM) CPT‐CAT‐II Urine Protein Tests 3061F Negative microalbuminuria test result documented and reviewed (DM) CPT‐CAT‐II Urine Protein Tests 3062F Positive macroalbuminuria test result documented and reviewed (DM) CPT‐CAT‐II Urine Protein Tests 11218‐5 Microalbumin [Mass/volume] in Urine by Test strip LOINC Urine Protein Tests 12842‐1 Protein [Mass/volume] in 12 hour Urine LOINC Urine Protein Tests 13705‐9 Albumin/Creatinine [Mass Ratio] in 24 hour Urine LOINC Urine Protein Tests 13801‐6 Protein/Creatinine [Mass Ratio] in 24 hour Urine LOINC Urine Protein Tests 13986‐5 Albumin/Protein.total in 24 hour Urine by Electrophoresis LOINC Urine Protein Tests 13992‐3 Albumin/Protein.total in Urine by Electrophoresis LOINC Urine Protein Tests 14956‐7 Microalbumin [Mass/time] in 24 hour Urine LOINC Urine Protein Tests 14957‐5 Microalbumin [Mass/volume] in Urine LOINC Urine Protein Tests 14958‐3 Microalbumin/Creatinine [Mass Ratio] in 24 hour Urine LOINC Urine Protein Tests 14959‐1 Microalbumin/Creatinine [Mass Ratio] in Urine LOINC Urine Protein Tests 1753‐3 Albumin [Presence]
    [Show full text]
  • Eosinophiluria in Relation to Pyelonephritis in Women
    Journal of Advanced Laboratory Research in Biology E-ISSN: 0976-7614 Volume 6, Issue 4, 2015 PP 108-110 https://e-journal.sospublication.co.in Research Article Eosinophiluria in relation to Pyelonephritis in Women Pritam Singh Ajmani* Department of Pathology, R.D. Gardi Medical College, Surasa, Ujjain, Madhya Pradesh-456006, India. Abstract: In the present study of outpatient settings, pyelonephritis was diagnosed by the history and physical examination and supported by urinalysis results. After a clinco-pathological confirmation of pyelonephritis in 100 female patients in the age group between 18-55 years were selected. The urine samples were subjected for routine urine analysis and urine sediment was stained with Wright-Giemsa stain. A total of 13% of these patients had eosinophils in urine. Eosinophiluria is defined as the presence of more than 1% eosinophils in urinary sediment under the microscope. Eosinophiluria proved to be good predictors of pyelonephritis, however, it is not specific. Positive test for pyuria of moderate to severe were seen in all (100%) of the cases. Microscopic hematuria was seen in 18% cases. We have found that Wright-Giemsa stain results show consistent results and eosinophils were more easily recognized. Demographic data collected were age, weight, gravidity, and parity. The gestational age of diagnosis was recorded. Keywords: Urine, Wright-Giemsa Stain, Eosinophiluria. 1. Introduction 3. Microscopic Pyuria. 4. Gross Hematuria. Pyelonephritis is a common bacterial infection of 5. Microscopic Hematuria. the renal pelvis and kidney that usually results from 6. WBC casts Indicative of renal origin. ascent of a bacterial pathogen up the ureters from the 7.
    [Show full text]
  • USMLE and COMLEX II
    USMLE and COMLEX Review Nephrology Supplement Glomerulonephritis, Acute Tubular Necrosis and Acute Interstitial Nephritis Northwestern Medical Review www.northwesternmedicalreview.com Lansing, Michigan 2014-2015 1. What is Tamm-Horsfall glycoprotein (THP)? Matching (4 – 15): Match the following urinary casts with the descriptions, conditions, or questions _______________________________________ presented hereafter: _______________________________________ A. Bacterial casts _______________________________________ B. Crystal casts _______________________________________ C. Epithelial casts D. Fatty casts _______________________________________ E. Granular casts _______________________________________ F. Hyaline casts G. Pigment casts H. Red blood cell casts 2. What is a urinary cast? I. Waxy casts J. White blood cell casts _______________________________________ _______________________________________ 4. These types of casts are by far the most common _______________________________________ urinary casts. They are composed of solidified Tamm-Horsfall mucoprotein and secreted from _______________________________________ tubular cells under conditions of oliguria, _______________________________________ concentrated urine, and acidic urine. _______________________________________ _______________________________________ _______________________________________ 5. These types of casts are pathognomonic of acute tubular necrosis (ATN) and at times are 3. What are the major types of urinary casts? described as “muddy brown casts”. _______________________________________
    [Show full text]
  • Drug Induced Nephropathy Cases
    Drug Induced Nephropathy Cases 1. H.H., 43 y.o., 80 kg male being treated for gram-negative septic shock • Admitted to hospital 6 days ago, and has spent the last 3 days intubated in the ICU because of hypotension, respiratory failure, and altered mental status. On admission, H.H. was started on ceftriaxone 2 g IV daily, gentamicin 140 mg IV q8h. • Admission labs: – BUN 13 mg/dL (5-20) – SCr 0.9 mg/dL (0.5-1.2) – Serial, blood, urine, and sputum cultures were positive for Acinetobacter baumanii sensitive to ceftriaxone and gentamicin. • Current medications – Ceftriaxone 2 g IV daily – Gentamicin 140 mg IV q8h. – Norepinephrine IV 18 mcg/min – Pancuronium 0.02 mg/kg IV q3h – Famotidine 20 mg IV q12h – Lorazepam IV 2 mg/hr • Today (hospital day 7) vital signs: – Temp 101.5 F (38.6 C) – BP 90/40 mmHg – Pulse 135 beats/min – Respirations 20 breaths/min • Labs: • BUN 67 mg/dL • SCr 5.4 mg/dL • WBC 16,700 cells/mm3 • Urinalysis: – Many WBC (0-5) – 3% RBC casts (0-1%) – Granular casts – Osmolality 250 mOsm/kg (400-600) • Serum gentamicin with last dose: – Peak 15 mg/dL (target 6-10) – Trough 9.1 mg/dL (target <2) a) Circle the renal parameters that are abnormal. b) What drug is most likely associated with the abnormal renal labs? 1 c) What information did you use to arrive at your assessment? 2. J.S., 50 y.o. female with cellulitus • In hospital blood and wound cultures were positive for methicillin-sensitive Staphylococcus aureus • Received 2 full days nafcillin 2 g IV q4h and then was discharged home on dicloxacillin 500 mg PO QID x 14 d • 10 days post discharge, J.S.
    [Show full text]